A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs KLH 2109 (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms EDELWEISS
- Sponsors ObsEva
- 23 Jan 2018 Planned End Date changed from 1 May 2019 to 1 Jul 2019.
- 23 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2018.
- 07 Nov 2017 According to an ObsEva media release, approximately 330 patients are expected to be randomized, and primary endpoint efficacy results continue to be anticipated in mid-2018.